Boehringer Ingelheim Vetmedica GmbH

Company Premium

Boehringer Ingelheim Animal Health Business Unit

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of 4 billion euros in 2019 and presence in more than 150 markets.

As the lives of animals and humans are intertwined, across the globe, our 10,000 employees are dedicated to enhancing the well-being of both – through science and innovation, as well as with their commitment and passion.

Respect for animals, people and the environment is at the heart of what we do. We develop medicines, services and innovative digital technologies to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society- threatening diseases.

For more information visit: www.boehringer-ingelheim.com/animal-health/overview

 

Send message

Clinical case: Bowel Oedema

This case study describes an outbreak in a commercial unit which proved difficult to stop without vaccine. Since 2014 an increasing number of cases of this disease have been reported in Europe though it remains unclear why it has reappeared.

The challenge of Porcine Circovirus type 2 (PCV2) intra-specific taxonomic classification

All available vaccines in the European and North-American market are based on PCV2a genotype, while the most prevalent ones are PCV2b and PCV2d ones. Although significant level of cross-protection among these three genotypes has been demonstrated, it would be interesting to assess if vaccine efficiency would be equivalent in front of all these different genotypes.

How PCV2 vaccines work

19-Jan-2016
Despite not having a consistent post-vaccination serological reaction, vaccinated animals behave differently from unvaccinated animals under field conditions.The article explains why vaccines offer protection.

Contact:

Contact us using the following form.

Boehringer Ingelheim Vetmedica GmbH is present in the following categories